Anti-IL-10R antibody improves the therapeutic efficacy of targeted liposomal oligonucleotides

Journal of Controlled Release

Volumn 138, Issue 2, 2009, Pages 122-127

  Brignole, Chiara ^a   Marimpietri, Danilo ^a   Pastorino, Fabio ^a   Di Paolo, Daniela ^a   Pagnan, Gabriella ^a   Loi, Monica ^a   Piccardi, Federica ^b   Cilli, Michele ^b   Tradori Cappai, Andrea ^c   Arrigoni, Gianluigi ^d   Pistoia, Vito ^a   Ponzoni, Mirco ^a  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c Prodotti Gianni SpA   (Italy)

^d SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Anti IL 10R antibody; Combination immunotherapy; CpG oligodeoxynucleotides; Neuroblastoma; Targeted liposomes

Indexed keywords

ANTI-IL-10R ANTIBODY; COMBINATION IMMUNOTHERAPY; CPG OLIGODEOXYNUCLEOTIDES; NEUROBLASTOMA; TARGETED LIPOSOMES;

ANTIBODIES; CELL MEMBRANES; IMMUNOLOGY; LIPOSOMES; OLIGONUCLEOTIDES; PHOSPHOLIPIDS; TUMORS;

THERMOLUMINESCENCE;

CPG OLIGODEOXYNUCLEOTIDE; INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR ANTIBODY; LIPOSOME; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFICACY; EX VIVO STUDY; FEASIBILITY STUDY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LIFESPAN; LYMPH NODE; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CELL PROLIFERATION; CPG ISLANDS; FEMALE; GANGLIOSIDES; HUMANS; IMMUNITY, INNATE; INTERLEUKIN-10; LIPOSOMES; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEUROBLASTOMA; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-MYB; RECEPTORS, INTERLEUKIN-10; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67651235587     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2009.05.006     Document Type: Article

References (36)

1. Brodeur G.M. Neuroblastoma: biological insights into a clinical enigma. Nat. Rev. Cancer 3 3 (2003) 203-216
2. Maris J.M., Hogarty M.D., Bagatell R., and Cohn S.L. Neuroblastoma. Lancet 369 9579 (2007) 2106-2120
3. Mui B., Raney S.G., Semple S.C., and Hope M.J. Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles. J Pharmacol. Exp. Ther. 298 3 (2001) 1185-1192
4. Zarember K.A., and Godowski P.J. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J. Immunol. 168 2 (2002) 554-561
5. Wagner H. The immunobiology of the TLR9 subfamily. Trends Immunol. 25 7 (2004) 381-386
6. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., Matsumoto M., Hoshino K., Wagner H., Takeda K., and Akira S. A Toll-like receptor recognizes bacterial DNA. Nature 408 6813 (2000) 740-745
7. Pagnan G., Stuart D.D., Pastorino F., Raffaghello L., Montaldo P.G., Allen T.M., Calabretta B., and Ponzoni M. Delivery of c-myb antisense oligodeoxynucleotides to human neuroblastoma cells via disialoganglioside GD(2)-targeted immunoliposomes: antitumor effects. J. Natl. Cancer Inst. 92 3 (2000) 253-261
8. Brignole C., Pastorino F., Marimpietri D., Pagnan G., Pistorio A., Allen T.M., Pistoia V., and Ponzoni M. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs. J. Natl. Cancer Inst. 96 15 (2004) 1171-1180
9. Pastorino F., Brignole C., Marimpietri D., Sapra P., Moase E.H., Allen T.M., and Ponzoni M. Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res. 63 1 (2003) 86-92
10. Tamm I., Dorken B., and Hartmann G. Antisense therapy in oncology: new hope for an old idea?. Lancet 358 9280 (2001) 489-497
11. Couper K.N., Blount D.G., and Riley E.M. IL-10: the master regulator of immunity to infection. J. Immunol. 180 9 (2008) 5771-5777
12. Chouaib S., Asselin-Paturel C., Mami-Chouaib F., Caignard A., and Blay J.Y. The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol. Today 18 10 (1997) 493-497
13. Vicari A.P., Caux C., and Trinchieri G. Tumour escape from immune surveillance through dendritic cell inactivation. Semin. Cancer Biol. 12 1 (2002) 33-42
14. Raffaghello L., Pagnan G., Pastorino F., Cosimo E., Brignole C., Marimpietri D., Montaldo P.G., Gambini C., Allen T.M., Bogenmann E., and Ponzoni M. In vitro and in vivo antitumor activity of liposomal Fenretinide targeted to human neuroblastoma. Int. J. Cancer 104 5 (2003) 559-567
15. Liu Y., de Waal Malefyt R., Briere F., Parham C., Bridon J.M., Banchereau J., Moore K.W., and Xu J. The EBV IL-10 homologue is a selective agonist with impaired binding to the IL-10 receptor. J Immunol 158 2 (1997) 604-613
16. Ho A.S., and Moore K.W. Interleukin-10 and its receptor. Ther. Immunol. 1 3 (1994) 173-185
17. Liu Y., Wei S.H., Ho A.S., de Waal Malefyt R., and Moore K.W. Expression cloning and characterization of a human IL-10 receptor. J. Immunol. 152 4 (1994) 1821-1829
18. O'Farrell A.M., Liu Y., Moore K.W., and Mui A.L. IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: evidence for Stat3-dependent and -independent pathways. Embo. J. 17 4 (1998) 1006-1018
19. Stuart D.D., Kao G.Y., and Allen T.M. A novel, long-circulating, and functional liposomal formulation of antisense oligodeoxynucleotides targeted against MDR1. Cancer Gene Ther. 7 3 (2000) 466-475
20. Lode H.N., Xiang R., Varki N.M., Dolman C.S., Gillies S.D., and Reisfeld R.A. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. J. Natl. Cancer Inst. 89 21 (1997) 1586-1594
21. Vicari A.P., Chiodoni C., Vaure C., Ait-Yahia S., Dercamp C., Matsos F., Reynard O., Taverne C., Merle P., Colombo M.P., O'Garra A., Trinchieri G., and Caux C. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J. Exp. Med. 196 4 (2002) 541-549
22. Brignole C., Marimpietri D., Pastorino F., Nico B., Di Paolo D., Cioni M., Piccardi F., Cilli M., Pezzolo A., Corrias M.V., Pistoia V., Ribatti D., Pagnan G., and Ponzoni M. Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. J. Natl. Cancer Inst. 98 16 (2006) 1142-1157
23. Pastorino F., Brignole C., Di Paolo D., Nico B., Pezzolo A., Marimpietri D., Pagnan G., Piccardi F., Cilli M., Longhi R., Ribatti D., Corti A., Allen T.M., and Ponzoni M. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res. 66 20 (2006) 10073-10082
24. Basak G.W., Zapala L., Wysocki P.J., Mackiewicz A., Jakobisiak M., and Lasek W. Interleukin 15 augments antitumor activity of cytokine gene-modified melanoma cell vaccines in a murine model. Oncol. Rep. 19 5 (2008) 1173-1179
25. Jaleco A.C., Blom B., Res P., Weijer K., Lanier L.L., Phillips J.H., and Spits H. Fetal liver contains committed NK progenitors, but is not a site for development of CD34+ cells into T cells. J. Immunol. 159 2 (1997) 694-702
26. Zhang C., Zhang J., Niu J., Zhang J., and Tian Z. Interleukin-15 improves cytotoxicity of natural killer cells via up-regulating NKG2D and cytotoxic effector molecule expression as well as STAT1 and ERK1/2 phosphorylation. Cytokine 42 1 (2008) 128-136
27. Klebanoff C.A., Finkelstein S.E., Surman D.R., Lichtman M.K., Gattinoni L., Theoret M.R., Grewal N., Spiess P.J., Antony P.A., Palmer D.C., Tagaya Y., Rosenberg S.A., Waldmann T.A., and Restifo N.P. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc. Natl. Acad. Sci. U. S. A. 101 7 (2004) 1969-1974
28. Teague R.M., Sather B.D., Sacks J.A., Huang M.Z., Dossett M.L., Morimoto J., Tan X., Sutton S.E., Cooke M.P., Ohlen C., and Greenberg P.D. Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors. Nat. Med. 12 3 (2006) 335-341
29. Nakamura Y., Yamada N., Ohyama H., Nakasho K., Nishizawa Y., Okamoto T., Futani H., Yoshiya S., Okamura H., and Terada N. Effect of interleukin-18 on metastasis of mouse osteosarcoma cells. Cancer Immunol. Immunother. 55 9 (2006) 1151-1158
30. Hsiao Y.W., Liao K.W., Chung T.F., Liu C.H., Hsu C.D., and Chu R.M. Interactions of host IL-6 and IFN-gamma and cancer-derived TGF-beta1 on MHC molecule expression during tumor spontaneous regression. Cancer Immunol. Immunother. 57 7 (2008) 1091-1104
31. de Waal Malefyt R., Abrams J., Bennett B., Figdor C.G., and de Vries J.E. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med. 174 5 (1991) 1209-1220
32. Krieg A.M. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5 6 (2006) 471-484
33. Link B.K., Ballas Z.K., Weisdorf D., Wooldridge J.E., Bossler A.D., Shannon M., Rasmussen W.L., Krieg A.M., and Weiner G.J. Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J. Immunother. 29 5 (2006) 558-568
34. Friedberg J.W., Kim H., McCauley M., Hessel E.M., Sims P., Fisher D.C., Nadler L.M., Coffman R.L., and Freedman A.S. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood 105 2 (2005) 489-495
35. Guiducci C., Vicari A.P., Sangaletti S., Trinchieri G., and Colombo M.P. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 65 8 (2005) 3437-3446
36. Ohashi K., Kobayashi G., Fang S., Zhu X., Antonia S.J., Krieg A.M., and Sandler A.D. Surgical excision combined with autologous whole tumor cell vaccination is an effective therapy for murine neuroblastoma. J. Pediatr. Surg. 41 8 (2006) 1361-1368